Ropivacaine 0.1% + Ropivacaine 0.4%
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Relatively Healthy Volunteers
Conditions
Relatively Healthy Volunteers
Trial Timeline
Jul 1, 2013 → Nov 1, 2013
NCT ID
NCT01898689About Ropivacaine 0.1% + Ropivacaine 0.4%
Ropivacaine 0.1% + Ropivacaine 0.4% is a approved stage product being developed by Baxter for Relatively Healthy Volunteers. The current trial status is completed. This product is registered under clinical trial identifier NCT01898689. Target conditions include Relatively Healthy Volunteers.
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01898689 | Approved | Completed |